News

Soleno files for US approval of DCCR for hyperphagia

Soleno Therapeutics is seeking approval of diazoxide choline controlled-release (DCCR) tablets in the U.S. for Prader-Willi syndrome (PWS) patients, 4 and older, with excessive hunger. The filing of the new drug application with the U.S. Food and Drug Administration (FDA) follows positive data from an open-label extension…

PWS children who switch from DCCR see worsening hyperphagia: Trial

Prader-Willi syndrome (PWS) patients who switched from daily treatment with DCCR (diazoxide choline extended-release tablets) to a placebo experienced worsening excessive hunger, or hyperphagia, and greater body weight gains relative to those who stayed on DCCR. That’s according to top-line data from the new randomized withdrawal period of…